bimekizumab psoriatic arthritis
Selected indexed studies
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (Drugs Today (Barc), 2023) [PMID:36847624]
- Bimekizumab: A Review in Psoriatic Arthritis. (Drugs, 2024) [PMID:38703349]
- Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). (Lancet, 2023) [PMID:36493791]
_Worker-drafted node — pending editorial review._
Connections
bimekizumab psoriatic arthritis is a side effect of
Sources
- Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). (2023) pubmed
- Bimekizumab for the treatment of psoriatic arthritis. (2024) pubmed
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (2023) pubmed
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- Bimekizumab: A Review in Psoriatic Arthritis. (2024) pubmed
- Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. (2018) pubmed
- Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. (2024) pubmed
- PMID:40198019 (2023) pubmed
- Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). (2023) pubmed